Objective:To investigate and analyze the clinical effect of clopidogrel bisulfate tablets combined with aspirin enteric-coated tablets on acute myocardial infarction(AMI)patients.Methods:The study period was from Janu...Objective:To investigate and analyze the clinical effect of clopidogrel bisulfate tablets combined with aspirin enteric-coated tablets on acute myocardial infarction(AMI)patients.Methods:The study period was from January 2020 to December 2023,the sample source was 82 AMI patients admitted to our hospital,grouped into an observation group(n=41)and a control group(n=41)by the numerical table method.The patients in the control group were treated with aspirin enteric-coated tablets,and the patients in the observation group were treated with aspirin enteric-coated tablets combined with clopidogrel bisulfate.The clinical efficacy,coagulation indexes,and the incidence of cardiovascular adverse events between the two groups were compared.Results:The clinical efficacy of the observation group was higher than that of the control group(P<0.05);the platelet aggregation rate(PAR)of the observation group was lower than that of the con-trol group after treatment(P<0.05),and there was no significant difference in the prothrombin time(PT)and activated partial thromboplastin time(APTT)between the two groups(P>0.05).The incidence of cardiovascular adverse events in the observation group was lower than that of the control group(P<0.05).Conclusion:The treatment effect of clopidogrel bisulfate tablets combined with aspirin enteric-coated tablets on AMI patients is remarkable.It reduces the PAR and the incidence of cardiovascular adverse events,so this treatment method should be popularized.展开更多
Objective: To discuss the actual effect of ilaprazole enteric-coated tablets in the treatment of peptic ulcer patients. Methods: 200 peptic ulcer patients who received treatment from January to December 2023 were sele...Objective: To discuss the actual effect of ilaprazole enteric-coated tablets in the treatment of peptic ulcer patients. Methods: 200 peptic ulcer patients who received treatment from January to December 2023 were selected as the study sample, and all patients were randomly and evenly divided into the study group (n = 100) and the control group (n = 100), and the serum inflammatory factors and the disappearance time of symptoms were compared. Results: After treatment, the serum inflammatory factors in the observation group were better than those in the control group, and the time of belching and burning sensation in the observation group was shorter than that in the control group, all of which were statistically significant (P Conclusion: Ilaprazole enteric-coated tablets in the treatment of peptic ulcer have a good effect and can effectively improve the symptoms of patients with clinical signs, with reference significance.展开更多
A methodology(HPLC)proposed in this paper for simultaneously quantitative determination of ilaprazole and its related impurities in commercial tablets was developed and validated.The chromatographic separation was car...A methodology(HPLC)proposed in this paper for simultaneously quantitative determination of ilaprazole and its related impurities in commercial tablets was developed and validated.The chromatographic separation was carried out by gradient elution using an Agilent C8 column(4.6 mm×250 mm,5 mm)which was maintained at 25℃.The mobile phase composed of solvent A(methanol)and solvent B(solution consisting 0.02 mmol/l monopotassium phosphate and 0.025 mmol/l sodium hydroxide)was at a flow rate of 1.0 ml/min.The samples were detected and quantified at 237 nm using an ultraviolet absorbance detector.Calibration curves of all analytes from 0.5 to 3.5 mg/ml were good linearity(r≥0.9990)and recovery was greater than 99.5% for each analyte.The lower limit of detection(LLOD)and quantification(LOQ)of this analytical method were 10 ng/ml and 25 ng/ml for all impurities,respectively.The stress studies indicated that the degradation products could not interfere with the detection of ilaprazole and its related impurities and the assay can thus be considered stability-indicating.The method precisions were in the range of 0.41-1.21 while the instrument precisions were in the range of 0.38-0.95 in terms of peak area RSD% for all impurities,respectively.This method is considered stabilityindicating and is applicable for accurate and simultaneous measuring of the ilaprazole and its related impurities in commercial enteric-coated tablets.展开更多
目的探讨溶栓胶囊联合阿司匹林治疗颈动脉硬化斑块的疗效。方法选取100例颈动脉粥样硬化斑块患者作为研究对象,用随机数字表法分为观察组(55例,用溶栓胶囊联合阿司匹林肠溶片治疗)和对照组(45例,用阿司匹林肠溶片治疗)。观察2组治疗后...目的探讨溶栓胶囊联合阿司匹林治疗颈动脉硬化斑块的疗效。方法选取100例颈动脉粥样硬化斑块患者作为研究对象,用随机数字表法分为观察组(55例,用溶栓胶囊联合阿司匹林肠溶片治疗)和对照组(45例,用阿司匹林肠溶片治疗)。观察2组治疗后的临床疗效、斑块情况、中医症状积分、血流变指标和不良反应发生情况。结果治疗后,观察组的临床总有效率(96.36%)高于对照组(80.00%),P<0.05。观察组患者的内-中膜的厚度(intima media thickness,IMT)和斑块面积分别为(0.95±0.16)mm、(19.34±1.47)mm^(2),均低于对照组[(1.24±0.18)mm、(20.33±1.87)mm^(2)];管腔直径[(6.47±0.48)mm]大于对照组[(5.53±0.43)mm],P<0.05。治疗后,观察组患者的头晕、头刺痛、肢体麻木、口唇紫暗中医症候积分分别为(1.02±0.56)、(2.02±1.48)、(2.34±0.47)、(2.26±1.22)分,均低于对照组[(2.34±0.43)、(3.20±1.03)、(3.33±1.87)、(3.51±1.49)分],P<0.05。治疗后,观察组全血黏度低切、中切、高切及血浆黏度均低于对照组(P<0.05)。2组不良反应发生率比较差异无统计学意义(P>0.05)。结论溶栓胶囊联合阿司匹林肠溶片治疗颈动脉硬化斑块能提高临床疗效,改善斑块情况,降低中医证候积分,改善血流变指标,且无明显不良反应发生,安全性较高。展开更多
文摘Objective:To investigate and analyze the clinical effect of clopidogrel bisulfate tablets combined with aspirin enteric-coated tablets on acute myocardial infarction(AMI)patients.Methods:The study period was from January 2020 to December 2023,the sample source was 82 AMI patients admitted to our hospital,grouped into an observation group(n=41)and a control group(n=41)by the numerical table method.The patients in the control group were treated with aspirin enteric-coated tablets,and the patients in the observation group were treated with aspirin enteric-coated tablets combined with clopidogrel bisulfate.The clinical efficacy,coagulation indexes,and the incidence of cardiovascular adverse events between the two groups were compared.Results:The clinical efficacy of the observation group was higher than that of the control group(P<0.05);the platelet aggregation rate(PAR)of the observation group was lower than that of the con-trol group after treatment(P<0.05),and there was no significant difference in the prothrombin time(PT)and activated partial thromboplastin time(APTT)between the two groups(P>0.05).The incidence of cardiovascular adverse events in the observation group was lower than that of the control group(P<0.05).Conclusion:The treatment effect of clopidogrel bisulfate tablets combined with aspirin enteric-coated tablets on AMI patients is remarkable.It reduces the PAR and the incidence of cardiovascular adverse events,so this treatment method should be popularized.
文摘Objective: To discuss the actual effect of ilaprazole enteric-coated tablets in the treatment of peptic ulcer patients. Methods: 200 peptic ulcer patients who received treatment from January to December 2023 were selected as the study sample, and all patients were randomly and evenly divided into the study group (n = 100) and the control group (n = 100), and the serum inflammatory factors and the disappearance time of symptoms were compared. Results: After treatment, the serum inflammatory factors in the observation group were better than those in the control group, and the time of belching and burning sensation in the observation group was shorter than that in the control group, all of which were statistically significant (P Conclusion: Ilaprazole enteric-coated tablets in the treatment of peptic ulcer have a good effect and can effectively improve the symptoms of patients with clinical signs, with reference significance.
文摘A methodology(HPLC)proposed in this paper for simultaneously quantitative determination of ilaprazole and its related impurities in commercial tablets was developed and validated.The chromatographic separation was carried out by gradient elution using an Agilent C8 column(4.6 mm×250 mm,5 mm)which was maintained at 25℃.The mobile phase composed of solvent A(methanol)and solvent B(solution consisting 0.02 mmol/l monopotassium phosphate and 0.025 mmol/l sodium hydroxide)was at a flow rate of 1.0 ml/min.The samples were detected and quantified at 237 nm using an ultraviolet absorbance detector.Calibration curves of all analytes from 0.5 to 3.5 mg/ml were good linearity(r≥0.9990)and recovery was greater than 99.5% for each analyte.The lower limit of detection(LLOD)and quantification(LOQ)of this analytical method were 10 ng/ml and 25 ng/ml for all impurities,respectively.The stress studies indicated that the degradation products could not interfere with the detection of ilaprazole and its related impurities and the assay can thus be considered stability-indicating.The method precisions were in the range of 0.41-1.21 while the instrument precisions were in the range of 0.38-0.95 in terms of peak area RSD% for all impurities,respectively.This method is considered stabilityindicating and is applicable for accurate and simultaneous measuring of the ilaprazole and its related impurities in commercial enteric-coated tablets.
文摘目的探讨溶栓胶囊联合阿司匹林治疗颈动脉硬化斑块的疗效。方法选取100例颈动脉粥样硬化斑块患者作为研究对象,用随机数字表法分为观察组(55例,用溶栓胶囊联合阿司匹林肠溶片治疗)和对照组(45例,用阿司匹林肠溶片治疗)。观察2组治疗后的临床疗效、斑块情况、中医症状积分、血流变指标和不良反应发生情况。结果治疗后,观察组的临床总有效率(96.36%)高于对照组(80.00%),P<0.05。观察组患者的内-中膜的厚度(intima media thickness,IMT)和斑块面积分别为(0.95±0.16)mm、(19.34±1.47)mm^(2),均低于对照组[(1.24±0.18)mm、(20.33±1.87)mm^(2)];管腔直径[(6.47±0.48)mm]大于对照组[(5.53±0.43)mm],P<0.05。治疗后,观察组患者的头晕、头刺痛、肢体麻木、口唇紫暗中医症候积分分别为(1.02±0.56)、(2.02±1.48)、(2.34±0.47)、(2.26±1.22)分,均低于对照组[(2.34±0.43)、(3.20±1.03)、(3.33±1.87)、(3.51±1.49)分],P<0.05。治疗后,观察组全血黏度低切、中切、高切及血浆黏度均低于对照组(P<0.05)。2组不良反应发生率比较差异无统计学意义(P>0.05)。结论溶栓胶囊联合阿司匹林肠溶片治疗颈动脉硬化斑块能提高临床疗效,改善斑块情况,降低中医证候积分,改善血流变指标,且无明显不良反应发生,安全性较高。
